After receiving a positive recommendation in April from a European regulatory panel, Biogen Idec Inc. has won approval from the European Commission for its Avonex Pen to treat patients with relapsing multiple sclerosis.

The Avonex Pen is the self-administered form of the Weston biotech’s Avonex MS drug and requires once-weekly injections of the treatment.

SOURCE